- Cool Tool – PRIME-XV® T Cell CDM – The First Commercially Available Chemically-defined, Animal-component-free Medium for T Cell CulturePosted 1 hour ago
- Increasing Protein Production with Novel Cell-Ess Titer Boost without Affecting the Metabolic ProfilePosted 5 days ago
- Continuous Processing Optimization with Smarter ToolsPosted 6 days ago
- Cool Tool – Generation of Neural Stem Cells from AlphaSTEM Cultured Pluripotent Stem CellsPosted 1 week ago
- Synergizing Transient and Stable Protein Expression for Accelerated Biotherapeutic DevelopmentPosted 1 week ago
- Cell Culture Dish Top Ten Ask the Expert Sessions and Podcasts of 2016Posted 2 weeks ago
- A Look at the Current State of Continuous BioprocessingPosted 2 weeks ago
- Cool Tool – Biomek i-Series – Next Generation Automated Workstations Specifically Designed to Meet Evolving WorkflowsPosted 2 weeks ago
- Filling Industry Gaps with Dedicated Cell Therapy Fluid Transfer SetsPosted 3 weeks ago
- Cell Culture Monitoring – A Critical Component for Quality by Design in Cell TherapyPosted 3 weeks ago
Takeda Brings Cell Based Influenza Vaccine Production to Japan with Baxter’s Assistance
Takeda Pharmaceutical Company (Japan) recently announced they have received a 23.9 billion yen subsidy from the Japanese government to develop the production capability for new influenza vaccines. Last year, Takeda and Baxter entered into a license agreement for Baxter’s proprietary Vero cell culture based influenza vaccine technology. Baxter is one of the few companies in the world with a cell culture produced influenza vaccine.
Takeda plans begin shipments of vaccine in 2014 and will initially develop a vaccine to immunize against H5N1 avian flu. Takeda is expected to build capacity to produce sufficient vaccine for at least 40 million people
Takeda will set up a new facility at its Hikari plant and use Baxter’s Vero cell production technology to produce vaccines faster than conventional methods that rely on chicken eggs. Takeda and other major Japanese drug makers pulled out of flu vaccine production in the mid-1990’s after a legal change made immunizations voluntary. The legal challenge reduced demand for the vaccine.
The Vero cell line is a continuous cell line and has been in use for decades to produce Polio vaccine in the United States. Thus, the Vero cell line has a history of safety and regulatory acceptance. Cell based influenza production using Vero or MDCK cells has been gaining acceptance in Europe and other parts of the world. However, an influenza vaccine using cell based production has not yet been approved by the United States Food and Drug Administration (FDA). Approximately 160 million doses of influenza vaccine are produced for the United States market each year. The Production of US influenza vaccines rely on traditional egg based production that is considered slower and more limited in scale than newer cell based technology.
For further reading, please see:
- Takeda Selected as Recipient of Government Subsidy for Developing Cell Culture-Based Influenza Vaccine – http://finchannel.com/news_flash/Pharmacy/93267_Takeda_Select_as_Recipient_of_Government_Subsidy_for_Developing_Cell_Culture-Based_Influenza_Vaccine/
- Takeda Press Release – http://www.takeda.com/press/article_42800.html
- Baxter Press Release – http://www.baxter.com/press_room/press_releases/2010/10_21_10-third_qtr_earnings.html